Amgen’s Mvasi Biosimilar Overtakes Avastin In The US
California-Based Giant Enjoyed Biosimilars Sales Of $1.7bn Last Year
Amgen enters 2021 with a five-strong global biosimilars portfolio, spearheaded by its market-leading bevacizumab and trastuzumab products in the US. Management explained the contrasting fates of the two oncology biosimilars as it published full-year financial results.
You may also be interested in...
Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.
Several biosimilars to Roche’s Avastin are now available in Europe following market formation in June last year, adding to Roche’s woes for its legacy oncology drugs, including MabThera/Rituxan and Herceptin.
The royalties for Pfizer’s Ruxience biosimilar, which has achieved a near 25% penetration rate in the US market, are to fall into the hands of another party following an agreement by original holder Aptevo Therapeutics. Teva’s Truxima is reported to be market leader in the US.